28 January 2016 - AstraZeneca today announced that the US FDA has granted breakthrough therapy designation for the oral poly ADP-ribose polymerase inhibitor Lynparza (olaparib), for the monotherapy treatment of BRCA1/2 or ATM gene mutated metastatic castration resistant prostate cancer in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide).

For more details, go to: https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/Lynparza-Olaparib-granted-Breakthrough-Therapy-Designation-by-US-FDA-for-treatment-of-BRCA1-2-or-ATM-gene-mutated-metastatic-Castration-Resistant-Prostate-Cancer-28012016.html